Momentis Surgical™ has secured two significant FDA 510(k) clearances for its Anovo™ robotic surgical platform, the world’s first single-port robotic system. These approvals mark a major advancement in minimally invasive surgical robotics.
The Anovo® robotic console is the only FDA-authorized surgical robotic system featuring miniature humanoid-shaped robotic arms.
Initially granted FDA De Novo marketing authorization for transvaginal benign surgical procedures, including benign hysterectomy, Anovo® has now expanded from the gynecology surgery market into general surgery with additional FDA approval for laparoscopic ventral hernia repairs. The latest 510(k) clearance introduces the next-generation console, enabling new and improved control.
The system delivers exceptional capabilities, including retroflexion and anteflexion through a single incision, enhanced haptic feedback, real-time video annotation, and a floor-mounted configuration that significantly reduces docking and draping times. Its advanced system architecture supports future data-driven upgrades, ensuring ongoing innovation and adaptability.
Anovo® is cost-efficient, readily available, and enhances accessibility to robotic-assisted surgery. It minimizes invasiveness and improves patient outcomes, empowering physicians to enhance patients’ quality of life and mortality like never before.
